Korea Investment CORP has reduced its stake in Union Pacific Corporation by 7.4% in the fourth quarter, selling 35,217 shares and now owning 439,096 shares valued at over $101 million. Despite this, other institutional investors have increased their holdings, and hedge funds and other institutional investors collectively own 80.38% of the company's stock. Union Pacific recently posted strong earnings, exceeding analyst estimates, and declared a quarterly dividend of $1.38 per share.

Pfizer (NYSE:PFE) has been highlighted as one of the best longevity stocks to buy, based on recent FDA approvals and promising clinical trial results. The company recently secured expanded FDA indications for Hympavzi to treat hemophilia and presented detailed Phase 2b results for its investigational GLP-1 receptor agonist, berobenatide, for diabetes. Additionally, Pfizer announced positive progression-free and overall survival results from its Phase 3 Breakwater trial.

JPMorgan and Mizuho have both raised their price targets for UnitedHealth Group (UNH), citing updated healthcare service models and a more stable policy environment in the managed care sector. Additionally, BofA upgraded UNH to Buy, indicating that strong Q1 results suggest improving utilization trends. The article notes that while UNH presents investment potential, some AI stocks may offer higher returns in a shorter timeframe.

Abbott Laboratories (ABT) is highlighted as one of the top longevity stocks, with recent announcements focusing on its advancements in diabetes care, including new data on diabetic ketoacidosis (DKA) and the CE Mark for its dual glucose-ketone sensing technology, Libre Duo. The company also secured reaffirmation for Cologuard and Cologuard Plus as preferred colorectal cancer screening options. Despite acknowledging ABT's potential, the article suggests that other AI stocks might offer greater returns.

Korea Investment CORP has reduced its stake in Lam Research Corporation (NASDAQ:LRCX) by 7.0% in the fourth quarter, selling 80,010 shares. Despite this, other institutional investors have acquired new positions, and insider selling has also occurred. The semiconductor company reported strong earnings, beating analyst estimates, and has received "Buy" ratings from several analysts with increased price targets.

Amgen Inc. (NASDAQ:AMGN) is highlighted as one of the top 7 longevity stocks to consider. The company recently announced positive Phase 3 data for its drug Repatha, which significantly reduced cardiovascular risks in diabetic patients. Despite a recent price target reduction by Goldman Sachs due to an IRS dispute, Amgen also secured marketing authorization for Imdylltra in Europe for lung cancer therapy.

Ieq Capital LLC increased its stake in General Dynamics Corporation (NYSE:GD) by 22.9% in the fourth quarter, purchasing an additional 25,450 shares to own a total of 136,465 shares valued at $45.94 million. Other institutional investors have also adjusted their holdings in GD, with several analysts maintaining "Buy" or "Hold" ratings and a consensus target price of $388.40. General Dynamics reported strong Q4 earnings, surpassing analyst estimates, and announced a quarterly dividend of $1.59 per share.

Ieq Capital LLC significantly increased its stake in Edison International (NYSE:EIX) by 90.3% in the fourth quarter, bringing its total holdings to 1,157,367 shares valued at $69.47 million. Other institutional investors also boosted their positions, with insider Peter J. Taylor selling 500 shares. Analysts currently have a "Hold" consensus rating on the stock with an average target price of $72.64.

Ironvine Capital Partners LLC has reduced its stake in Labcorp Holdings Inc. by 22.2% in the fourth quarter, now holding 65,549 shares valued at $16.45 million, making it their 22nd largest position. Other institutional investors have recently bought stakes in Labcorp, while analysts have set various price targets, with the company currently holding a "Moderate Buy" rating. Insider transactions also show CEO Adam H. Schechter and EVP Kathryn W. Kyle selling shares, reducing their ownership.

Royal London Asset Management Ltd. reduced its stake in Autodesk, Inc. (NASDAQ:ADSK) by 6.4% in the fourth quarter, selling 36,328 shares and bringing its total holdings to 531,978 shares worth approximately $157.47 million. Despite this reduction, other institutional investors significantly increased their positions in ADSK, and analysts maintain a "Moderate Buy" consensus rating with an average target price of $327.21 for the software company.